New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): Studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry

Journal of Mass Spectrometry

Volumn 39, Issue 3, 2004, Pages 255-261

  Staack, Roland F ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

1 (3,4 methylenedioxybenzyl)piperazine; Gas chromatography mass spectrometry; MDBP; Metabolism; Urine

Indexed keywords

ACYLATION; AROMATIC COMPOUNDS; BODY FLUIDS; GAS CHROMATOGRAPHY; HYDROLYSIS; LIVING SYSTEMS STUDIES; MASS SPECTROMETRY; METABOLISM;

DESIGNER DRUGS; HUMAN URINE;

DRUG PRODUCTS;

1 (3,4 METHYLENEDIOXYBENZYL)PIPERAZINE; BENZYLAMINE DERIVATIVE; DESIGNER DRUG; DIAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DEALKYLATION; DEGRADATION; DOSE CALCULATION; GAS CHROMATOGRAPHY; GLUCURONIDATION; HYDROLYSIS; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; METHYLATION; MICROWAVE RADIATION; NONHUMAN; PRIORITY JOURNAL; RAT; SULFATION; TOXICOKINETICS; URINALYSIS;

ANIMALS; DESIGNER DRUGS; DIOXOLES; DRUG EVALUATION, PRECLINICAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; PIPERAZINES; RATS; RATS, WISTAR;

EID: 1642367231     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.556     Document Type: Article

References (39)

1. Staack RF, Fritschi G, Maurer HH. In Proceedings of the 39th International TIAFT Meeting in Prague, 2001, Balikova M, Navakova E (eds), Charles University: Prague, 2002; 115.
2. Drug Enforcement Administration-Department of Justice. Schedules of controlled substances: Temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into schedule I. Fed. Regist. 2002; 67: 59 161.
3. Shulgin A. In Pihkal, a Chemical Love Story, Joy D (ed.). Transform Press: Berkeley, CA, 1991; 815.
4. Trachsel D, Richard N. Psychedelische Chemie (2nd edn). Nachtschatten Verlag: Solothurn, 2000.
5. 3H]3,4-methylenedioxymethamphetamine in mice. Eur. J. Pharmacol. 1993; 228: 247.
6. Hashimoto K, Maeda H, Goromaru T. Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain. Brain Res. 1992; 590: 341.
7. Bye C, Munro FA, Peck AW, Young PA. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur. J. Clin. Pharmacol. 1973; 6: 163.
8. Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur. J. Clin. Pharmacol. 1973; 6: 170.
9. Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 2003; 38: 659.
10. Maurer HH. Screening procedures for simultaneous detection of several drug classes used in the high throughput toxicological analysis and doping control [review]. Comb. Chem. High Throughput Screen. 2000; 3: 461.
11. Maurer HH. In Advances in Forensic Applications of Mass Spectrometry, Yinon J (ed.). CRC Press: Boca Raton, FL 2003; in press.
12. Staack RF, Fehn J, Maurer HH. New designer drug paramethoxymethamphetamine: Studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 789: 27.
13. Paul LD, Maurer HH. Studies on the metabolism and toxicological detection of the Eschscholtzia californica alkaloids californine and protopine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 789: 43.
14. Beitia G, Cobreros A, Sainz L, Cenarruzabeitia E. 3,4-Methylenedioxymethamphetamine (ecstasy)-induced hepatotoxicity: effect on cytosolic calcium signals in isolated hepatocytes. Liver 1999; 19: 234.
15. Carvalho M, Carvalho F, Bastos ML. Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxymethamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch. Toxicol. 2001; 74: 789.
16. Garbino J, Henry JA, Mentha G, Romand JA. Ecstasy ingestion and fulminant hepatic failure: Liver transplantation to be considered as a last therapeutic option. Vet. Hum. Toxicol. 2001; 43: 99.
17. Jones AL, Simpson KJ. Review article: Mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 1999; 13: 129.
18. Durand F, Samuel D, Bernuau J, Saliba F, Pariente EA, Marion S, Benhamou JP, Bismuth H. Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation. J. Hepatol. 1992; 15: 144.
19. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2002; 773: 35.
20. Maurer HH, Bickeboeller-Friedrich J. Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. J. Anal. Toxicol. 2000; 24: 340.
21. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001; 23: 61.
22. McKay AF, Ott WL, Taylor GW, Buchanan MN, Crooker JF. Diazohydrocarbons. Can. J. Res. 1950; 28: 683.
23. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites (4th edn). Agilent Technologies: Palo Alto, CA, in press.
24. McLafferty FW, Turecek F. Interpretation of Mass Spectra (4th edn). University Science Books: Mill Valley, CA: 1993.
25. Smith RM, Busch KL. Understanding Mass Spectra - A Basic Approach. Wiley: New York, 1999.
26. Kraemer T, Bickeboeller-Friedrich J, Maurer HH. On the metabolism of the amphetamine-derived antispasmodic drug mebeverine: Gas chromatography-mass spectrometry studies on rat liver microsomes and on human urine. Drug Metab. Dispos. 2000; 28: 339.
27. Ioannides C. Enzyme Systems that Metabolise Drugs and Other Xenobiotics, Wiley: New York, 2001.
28. Koh S, Arai M, Kawai S, Okamoto M. Assay of catechol O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 1981; 226: 461.
29. Nissinen E, Mannisto P. Determination of catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. Anal. Biochem. 1984; 137: 69.
30. Maurer HH, Bickeboeller-Friedrich J, Kraemer T. Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine. J. Chromatogr. B 2000; 739: 325.
31. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP): Gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom. 2003; 38: 971.
32. Ensslin HK, Maurer HH, Gouzoulis E, Hermle L, Kovar KA. Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab. Dispos. 1996; 24: 813.
33. Maurer HH. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 1996; 18: 465.
34. Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs. Biochem. Pharmacol. 2000; 59: 1563.
35. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol. Lett. 2000; 112: 133.
36. Kovats E. Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone. Helv. Chim. Acta 1958; 41: 1915.
37. de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special Issue of the TIAFT Bulletin) (3rd edn). VCH: Weinheim, 1992.
38. Pfleger K, Maurer HH, Weber A. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites, Part 5 (2nd edn). Wiley-VCH: Weinheim, in press.
39. Staack RF, Maurer HH. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites and differentiation from an intake of structurally related medicaments in urine using gas chromatography-mass spectrometry. J. Chromatogr. B 2003; 798: 333.